- Alimera Sciences ( NASDAQ: ALIM ) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation.
- ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement for Iluvien by the Italian Medicines Agency (AIFA), Alimera said in a statement on Friday.
- The indication was for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- ALIM said it would launch Iluvien through its Italian distribution partner, ophthalmic company SIFI.
- It did not disclose the pricing determination for Iluvien.
- ALIM stock closed marginally higher at $5.32 on Thursday.
For further details see:
Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation